Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | -1.66%3.49B | --1.7B | 8.36%7.08B | 22.66%3.55B | ---- | 307.10%6.53B | 216.39%2.9B | ---- | -44.15%1.61B | -43.52%915M |
| Operating income | -1.66%3.49B | 8.36%7.08B | 22.66%3.55B | 307.10%6.53B | 216.39%2.9B | -44.15%1.61B | -43.52%915M | |||
| Operating expenses | ||||||||||
| Gross profit | ||||||||||
| Employee expense | -6.98%-644M | ---- | -6.53%-1.22B | -6.36%-602M | ---- | -11.24%-1.15B | -7.60%-566M | ---- | 1.62%-1.03B | 4.01%-526M |
| Depreciation and amortization | -3.13%-395M | ---- | 6.80%-754M | 0.00%-383M | ---- | -7.87%-809M | -1.06%-383M | ---- | -2.32%-750M | -5.87%-379M |
| Special items of operating profit | -5.26%-540M | ---- | -10.84%-1.04B | -16.86%-513M | ---- | -99.79%-941M | -56.23%-439M | ---- | 23.04%-471M | 7.26%-281M |
| Operating profit | -14.97%585M | 11.51%1.37B | 58.89%688M | 205.33%1.23B | 175.44%433M | -116.57%-1.16B | -203.70%-574M | |||
| Financing income | -20.69%23M | ---- | 39.58%67M | 7.41%29M | ---- | 152.63%48M | 2,600.00%27M | ---- | 850.00%19M | 0.00%1M |
| Financing cost | 11.36%-195M | 4.40%-174M | 20.30%-424M | 23.34%-220M | 16.51%-182M | -19.82%-532M | -51.85%-287M | -39.74%-218M | -19.03%-444M | 0.00%-189M |
| Special items of earning before tax | ---- | ---- | --1M | --1M | ---- | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | -17.07%413M | 36.30%1.01B | 187.86%498M | 146.66%741M | 122.70%173M | -51.96%-1.59B | -102.12%-762M | |||
| Tax | ---- | ---- | 171.43%35M | 2,050.00%43M | ---- | -916.67%-49M | 0.00%2M | ---- | 300.00%6M | 150.00%2M |
| After-tax profit from continuing operations | -23.66%413M | 51.01%1.05B | 209.14%541M | 143.74%692M | 123.03%175M | -50.95%-1.58B | -99.48%-760M | |||
| Earning after tax | -23.66%413M | -31.99%202M | 51.01%1.05B | 209.14%541M | 3,070.00%297M | 143.74%692M | 123.03%175M | 97.02%-10M | -50.95%-1.58B | -99.48%-760M |
| Profit attributable to shareholders | -23.66%413M | 51.01%1.05B | 209.14%541M | 143.74%692M | 123.03%175M | -50.95%-1.58B | -99.48%-760M | |||
| Basic earnings per share | -23.77%0.051 | 50.82%0.1291 | 209.72%0.0669 | 143.79%0.0856 | 123.00%0.0216 | -50.97%-0.1955 | -99.36%-0.0939 | |||
| Diluted earnings per share | -23.77%0.051 | 50.82%0.1291 | 209.72%0.0669 | 143.79%0.0856 | 123.00%0.0216 | -50.97%-0.1955 | -99.36%-0.0939 | |||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | IAS | UAS | IAS | IAS | UAS | IAS | IAS | UAS | IAS | IAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | Deloitte Touche Tohmatsu CPA LLP | -- | -- | Deloitte Touche Tohmatsu CPA LLP | -- | -- | Deloitte Touche Tohmatsu CPA LLP | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.